These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. McDonald CM; Henricson EK; Abresch RT; Duong T; Joyce NC; Hu F; Clemens PR; Hoffman EP; Cnaan A; Gordish-Dressman H; Lancet; 2018 Feb; 391(10119):451-461. PubMed ID: 29174484 [TBL] [Abstract][Full Text] [Related]
24. Quality of life in Duchenne muscular dystrophy: the subjective impact on children and parents. Baiardini I; Minetti C; Bonifacino S; Porcu A; Klersy C; Petralia P; Balestracci S; Tarchino F; Parodi S; Canonica GW; Braido F J Child Neurol; 2011 Jun; 26(6):707-13. PubMed ID: 21482750 [TBL] [Abstract][Full Text] [Related]
25. Descriptive epidemiology of selected heritable birth defects in Texas. Moffitt KB; Abiri OO; Scheuerle AE; Langlois PH Birth Defects Res A Clin Mol Teratol; 2011 Dec; 91(12):990-4. PubMed ID: 22102535 [TBL] [Abstract][Full Text] [Related]
26. Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta. Orioli IM; Castilla EE; Scarano G; Mastroiacovo P Am J Med Genet; 1995 Nov; 59(2):209-17. PubMed ID: 8588588 [TBL] [Abstract][Full Text] [Related]
27. Targeting mRNA splicing as a potential treatment for Duchenne muscular dystrophy. Kole R; Leppert BJ Discov Med; 2012 Jul; 14(74):59-69. PubMed ID: 22846203 [TBL] [Abstract][Full Text] [Related]
28. Approaching therapies for boys with Duchenne muscular dystrophy. Parent Project Muscular Dystrophy. Annual conference in Cincinnati/Ohio, 13-16 July 2006. Scheuerbrandt G Acta Myol; 2006 Oct; 25(2):77-97. PubMed ID: 18593009 [No Abstract] [Full Text] [Related]
33. The birth prevalence rates for the skeletal dysplasias. Orioli IM; Castilla EE; Barbosa-Neto JG J Med Genet; 1986 Aug; 23(4):328-32. PubMed ID: 3746832 [TBL] [Abstract][Full Text] [Related]
34. Advances in Duchenne muscular dystrophy gene therapy. van Deutekom JC; van Ommen GJ Nat Rev Genet; 2003 Oct; 4(10):774-83. PubMed ID: 14526374 [TBL] [Abstract][Full Text] [Related]
35. Factors Associated With Health-Related Quality of Life in Children With Duchenne Muscular Dystrophy. Wei Y; Speechley KN; Zou G; Campbell C J Child Neurol; 2016 Jun; 31(7):879-86. PubMed ID: 26863997 [TBL] [Abstract][Full Text] [Related]
36. New Survival Target for Duchenne Muscular Dystrophy. Villanova M; Kazibwe S Am J Phys Med Rehabil; 2017 Feb; 96(2):e28-e30. PubMed ID: 28099279 [TBL] [Abstract][Full Text] [Related]
37. Results of a prospective pilot trial on mobility after whole body vibration in children and adolescents with osteogenesis imperfecta. Semler O; Fricke O; Vezyroglou K; Stark C; Stabrey A; Schoenau E Clin Rehabil; 2008 May; 22(5):387-94. PubMed ID: 18441035 [TBL] [Abstract][Full Text] [Related]
38. Developmental charts for children with osteogenesis imperfecta, type I (body height, body weight and BMI). Graff K; Syczewska M Eur J Pediatr; 2017 Mar; 176(3):311-316. PubMed ID: 28058531 [TBL] [Abstract][Full Text] [Related]
39. Advances in the orthopedic management of osteogenesis imperfecta. Laron D; Pandya NK Orthop Clin North Am; 2013 Oct; 44(4):565-73. PubMed ID: 24095072 [TBL] [Abstract][Full Text] [Related]